Proton Pompa İnhibitörü Kullanımında Fayda ve Risklerin Güncel Literatür Işığında Değerlendirilmesi

Baron JH. The history of acid inhibition. Yale J Biol Med. 1994;67(3-4):97-106.
Simon M, Levy EI, Vandenplas Y. Safety considerations when managing gastro-esophageal reflux disease in infants. Expert Opin Drug Saf. 2021;20(1):37-49. doi:10.1080/14740338.2020.1843630
Zou S, Ouyang M, Cheng Q, Shi X, Sun M. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024;44(2):171-183. doi:10.1002/phar.2899
Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11(1):27-37. doi:10.5009/gnl15502
Ben Ghezala I, Luu M, Bardou M. An update on drug-drug interactions associated with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2022;18(5):337-346. doi:10.1080/17425255.2022.2098107
El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447-460. doi:10.1080/17425255.2018.1461835
Savarino V, Marabotto E, Zentilin P, et al. The appropriate use of proton-pump inhibitors. Minerva Med. 2018;109(5):386-399. doi:10.23736/S0026-4806.18.05705-1
Gommers LMM, Hoenderop JGJ, de Baaij JHF. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022;235(4):e13846. doi:10.1111/apha.13846
Freeman R, Dabrera G, Lane C, et al. Association between use of proton pump inhibitors and non-typhoidal salmonellosis identified following investigation into an outbreak of Salmonella Mikawasima in the UK, 2013. Epidemiol Infect. 2016;144(5):968-975. doi:10.1017/S0950268815002332
Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500-6515. doi:10.3748/wjg.v23.i35.6500
Namikawa K, Björnsson ES. Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive? Int J Mol Sci. 2024;25(10):5459. doi:10.3390/ijms25105459
Choudhury A, Jena A, Jearth V, et al. Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2023;17(5):479-487. doi:10.1080/17474124.2023.2204229
Boxer M. Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors. EJHaem. 2020;1(2):548-551. doi:10.1002/jha2.96
Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021;76(1):13-21. doi:10.1016/j.therap.2020.06.019
Paudel Y, Najam B, Desai HN, et al. Use of Proton Pump Inhibitors and Risk of Fracture in Adults: A Review of Literature. Cureus. 2023;15(12):e49872. doi:10.7759/cureus.49872
Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161-1168. doi:10.1007/s00198-012-2112-9
Sharara AI, El-Halabi MM, Ghaith OA, et al. Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism. 2013;62(4):518-526. doi:10.1016/j.metabol.2012.09.011
Zirk-Sadowski J, Masoli JA, Strain WD, et al. Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients. Am J Gastroenterol. 2017;112(3):520-523. doi:10.1038/ajg.2016.584
Ozen G, Pedro S, Wolfe F, Michaud K. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(8):1041-1047. doi:10.1136/annrheumdis-2019-215328
Hussain S, Siddiqui AN, Habib A, Hussain MS, Najmi AK. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int. 2018;38(11):1999-2014. doi:10.1007/s00296-018-4142-x
Hansen KE, Nieves JW, Nudurupati S, Metz DC, Perez MC. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women. Gastroenterology. 2019;156(4):926-934.e6. doi:10.1053/j.gastro.2018.11.023
Mortensen SJ, Mohamadi A, Wright CL, et al. Medications as a Risk Factor for Fragility Hip Fractures: A Systematic Review and Meta-analysis. Calcif Tissue Int. 2020;107(1):1-9. doi:10.1007/s00223-020-00688-1
Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26(10):2501-2507. doi:10.1007/s00198-015-3168-0
Bell EJ, Bielinski SJ, St Sauver JL, et al. Association of Proton Pump Inhibitors With Higher Risk of Cardiovascular Disease and Heart Failure. Mayo Clin Proc. 2021;96(10):2540-2549. doi:10.1016/j.mayocp.2021.02.025
Caetano C, Veloso M, Borda S. Proton pump inhibitors and dementia: what association?. Dement Neuropsychol. 2023;17:e20220048. doi:10.1590/1980-5764-DN-2022-0048
Ahmed A, Clarke JO. Proton Pump Inhibitors (PPI). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706-1719.e5. doi:10.1016/j.cgh.2016.05.018
Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28-35. doi:10.1136/gutjnl-2017-314605
Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133(3):755-760. doi:10.1053/j.gastro.2007.06.014
Hong HE, Kim AS, Kim MR, Ko HJ, Jung MK. Does the Use of Proton Pump Inhibitors Increase the Risk of Pancreatic Cancer? A Systematic Review and Meta-Analysis of Epidemiologic Studies. Cancers (Basel). 2020;12(8):2220. doi:10.3390/cancers12082220
Nguyen NTH, Huang CW, Wang CH, et al. Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A Nested Case-Control Study of 23 Million Individuals. Cancers (Basel). 2022;14(24):6083. doi:10.3390/cancers14246083
Dharmarajan TS. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. J Am Med Dir Assoc. 2021;22(1):15-22. doi:10.1016/j.jamda.2020.09.046
Lanas-Gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf. 2019;18(11):1043-1053. doi:10.1080/14740338.2019.1664470
Choi A, Noh Y, Jeong HE, et al. Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations. JAMA Netw Open. 2023;6(1):e2250366. doi:10.1001/jamanetworkopen.2022.50366
Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354-364.